Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Ecopipam - Emalex Biosciences

Alternative Names: EBS-101; Ecopipam HCl; Ecopipam Hydrochloride; PSYRX 101; SCH-39166

Latest Information Update: 04 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
  • Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
  • Phase II Speech disorders
  • Phase I/II Restless legs syndrome
  • Phase I Cardiovascular disorders
  • No development reported Gambling
  • Discontinued Cocaine-related disorders; Obesity; Schizophrenia

Most Recent Events

  • 27 Dec 2024 Emalex Biosciences completes a phase I pharmacokinetics trial (In volunteers) in USA (NCT06669091)
  • 05 Nov 2024 Emalex Biosciences initiates a phase I pharmacokinetics trial (In volunteers) in USA (NCT06669091)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Lesch-Nyhan-syndrome(In volunteers) in United Kingdom (PO, Controlled release)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

New Timelines Chart

We recently added a timeline chart on all drug profiles. You can choose the indication from the drop down menu near the top. The chart will show the time the drug spent in different phases as it progressed through development for that indication. The end result is a Gantt style chart illustrating how long the drug took in each phase. This new chart takes advantage of our longitudinal pipeline data which we have stored every month since 2004. Please use the thumbs up/down buttons to let us know your opinion about this new feature.